about
Neurofilament light chain: a biomarker for genetic frontotemporal dementiaClinical features and APOE genotype of pathologically proven early-onset Alzheimer disease.Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort.Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: detection of GRN mutations in a Spanish cohort.CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study.White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer's Disease.The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study.Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study.A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease.Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease.Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment.PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia.Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-β levels.Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease.Evolving brain structural changes in PSEN1 mutation carriers.Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe.Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease.White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels.Clinical and neuropathological variability in clinically isolated central nervous system Whipple's disease.Frontotemporal Dementia Caused by the P301L Mutation in the MAPT Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain.Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain.The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study.[A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease.Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints.Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive ImpairmentLarge APP locus duplication in a sporadic case of cerebral haemorrhageClinical applicability of diagnostic biomarkers in early-onset cognitive impairmentContribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures
P50
Q37208495-0B1B0E0B-5E57-42B4-8BB8-28555E3E1226Q37876053-259661A7-8360-413F-B4A9-6B143A264A92Q38266291-5FD769B2-2EF7-471B-A083-F5A9DCDE54C3Q38470633-B01F20F7-154F-44B7-88C0-D32277B13E9DQ39293214-2A537203-11A3-4183-903B-FC515E0FD36CQ39962785-B4085A4D-C595-4F30-B179-FAF0681DE906Q40306498-ED08A1E2-7740-4D06-AD5D-5BDA42700096Q41362886-5FE50EC1-883E-427D-A1DD-3688407417C8Q43408013-DD60F991-D834-4D9D-B246-34EF2AEF8FE2Q44222077-228377E1-8C31-4E8A-94A3-78F08DCC6B60Q44878048-B6A4F051-1369-4D30-84A1-06D8F7AC9E28Q45103735-D4BC56FA-A40F-4916-90D2-CB38362F0FA8Q45423370-253DE1DD-AF45-40E5-96FB-E07861CDBE62Q45758151-9DD97902-034B-40CA-9899-FE9DE682BECBQ46302166-45A8507D-294D-47E7-A410-DBAFB20BC071Q46629626-9F351E50-81C9-49A6-B07C-AFE54D947427Q46779502-E8A233DA-31DD-423C-9F83-B61CD77B84BBQ47641756-AE764ADE-1162-4BA6-9F67-874EEF3BF5CAQ48451469-27680198-C74A-4B84-9830-836E27779D46Q48671419-5DD0CBEA-7E8C-4E6D-8267-C5C13D5C43CBQ48818732-C230A381-8D65-4A20-AD13-A28E862E445EQ49960337-A0506368-4A43-4B20-B00E-D752A55E3AEFQ50483256-8E730AAA-5D8E-4F9E-A33C-B7E0CED949F3Q50908238-F35224AD-D759-4D16-93EC-86B0636DFED3Q50956949-8E041069-229C-4565-A3C3-14CA6BB7A8F3Q51012240-EDE88905-9900-4C81-B93C-2DD35CE66504Q51026968-903E3E5C-C96A-4CBB-98A7-4051367C49CBQ57814354-14C694F0-1882-448E-9A0D-A0E95ACE465BQ57814457-E3FA2D8C-694C-4526-9A8A-8D295C4EB81DQ91822915-F2B33CEC-9921-4C95-B0E2-34F6D48A2EF8Q92685561-97C6D2C1-2145-4F88-B6B6-AB738714B46F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mircea Balasa
@ast
Mircea Balasa
@en
Mircea Balasa
@es
Mircea Balasa
@nl
Mircea Balasa
@sl
type
label
Mircea Balasa
@ast
Mircea Balasa
@en
Mircea Balasa
@es
Mircea Balasa
@nl
Mircea Balasa
@sl
prefLabel
Mircea Balasa
@ast
Mircea Balasa
@en
Mircea Balasa
@es
Mircea Balasa
@nl
Mircea Balasa
@sl
P106
P21
P31
P496
0000-0002-1795-4228